Numerical Tech downgraded by Craig Hallum with a new price target
$NMTC
Medical/Dental Instruments
Health Care
Craig Hallum downgraded Numerical Tech from Buy to Hold and set a new price target of $2.00 from $6.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/29/2022 | $6.00 → $2.00 | Buy → Hold | Craig Hallum |
| 12/3/2021 | $5.75 | Buy | Alliance Global Partners |
| 11/15/2021 | $6.00 | Buy | Craig-Hallum |
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company's second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the f
Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance. This submission leverages the Company's proprietary OneRF® Ablation System RF generator platform for the treatment of trigeminal neuralgia, a chronic pain condition affecti
Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa. Dear Shareholders, In recent months, NeuroOne has achieved several significant milestones, including the expansion of our commercial partnership with Zimmer Biomet, progress towards the submission of a 510(k) filing to treat facial pain, and conti
EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 13, 2025, to discuss the Company's second quarter fiscal year 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the f
Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from Zimmer Biomet EDEN PRAIRIE, Minn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported financial results for the first quarter fiscal year 2025 ended December 31, 2024. First Quarter Financial Highlights Product revenue increased 235% to $3.3 million in the first quarter of fiscal year 2025, compared to $1.0 million in the first quarter of fiscal
EDEN PRAIRIE, Minn., Feb. 05, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal first quarter ended December 31, 2024, before market open on February 12, 2025. Management will host an investor conference call and webcast at 8:30 a.m. eastern time on Wednesday, February 12, 2025, to discuss the Company's first quarter 2025 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)
8-K - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
424B5 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
424B5 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Filer)
Craig Hallum downgraded Numerical Tech from Buy to Hold and set a new price target of $2.00 from $6.00 previously
Alliance Global Partners initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $5.75
Craig-Hallum initiated coverage of NeuroOne Medical Tech with a rating of Buy and set a new price target of $6.00
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement EDEN PRAIRIE, Minn., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which acquired Cardiovascular Systems, Inc. in April 2023. Mr. Volker held the role of Vice President and General Manager of International at
EDEN PRAIRIE, Minn., Jan. 18, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announces the appointment of Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs. Mr. Wilhelmy joins NeuroOne from HLT Medical, a subsidiary of the Bracco Group, where he was the Vice President Quality Assurance. Dave Rosa, CEO of NeuroOne Medical Technologies Corporation says, "Chad's appointment further strengthens our executive leadership team and deepens our capabilities as we build the pla
SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)
SC 13G - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)